Overview

The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepre

Status:
Completed

Trial end date:
2021-09-06

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.

Phase:

Phase 3

Details

Lead Sponsor:

Allergan

Treatments:

Antidepressive Agents
Cariprazine